These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9464359)

  • 21. Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect.
    Bali A; Malhotra S; Dhir H; Kumar A; Sharma A
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3041-4. PubMed ID: 19398330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
    J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
    Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C
    J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists.
    Secchi RL; Sung E; Hedley LR; Button D; Schreiber R
    Behav Brain Res; 2009 Sep; 202(2):192-7. PubMed ID: 19463701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
    Cuisiat S; Bourdiol N; Lacharme V; Newman-Tancredi A; Colpaert F; Vacher B
    J Med Chem; 2007 Feb; 50(4):865-76. PubMed ID: 17300168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
    Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
    J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Typical and atypical antipsychotic drugs target dopamine and cyclic AMP-regulated phosphoprotein, 32 kDa and neurotensin-containing neurons, but not GABAergic interneurons in the shell of nucleus accumbens of ventral striatum.
    Ma J; Ye N; Cohen BM
    Neuroscience; 2006 Sep; 141(3):1469-80. PubMed ID: 16781818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
    Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
    J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).
    Bolós J; Anglada L; Gubert S; Planas JM; Agut J; Príncep M; De la Fuente N; Sacristán A; Ortiz JA
    J Med Chem; 1998 Dec; 41(27):5402-9. PubMed ID: 9876110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
    Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
    Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interstrain differences in the content of excitatory and inhibitory amino acids in the brain of DBA/2J, Balb/c and C57BL/6 mice: characteristics of the effect of a dipeptide antipsychotic drug dilept].
    Shubenina EB; Kudrin VS; Klodt PM; Pokrovskiĭ AA; Gudasheva TA; Voronina TA; Ostrovskaia RU
    Eksp Klin Farmakol; 2008; 71(4):7-10. PubMed ID: 18819433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.
    Campiani G; Butini S; Fattorusso C; Trotta F; Gemma S; Catalanotti B; Nacci V; Fiorini I; Cagnotto A; Mereghetti I; Mennini T; Minetti P; Di Cesare MA; Stasi MA; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2005 Mar; 48(6):1705-8. PubMed ID: 15771414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromodulatory mechanism underlying the effect of the atypical dipeptide neuroleptic dilept.
    Retyunskaya MV; Guzevatykh LS; Bondarenko NA; Gudasheva TA; Ostrovskaya RU; Voronina TA
    Bull Exp Biol Med; 2003 Nov; 136(5):467-70. PubMed ID: 14968162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
    Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
    Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.